605 Long-term management of moderate-to-severe plaque psoriasis: Maintenance of treatment success following cessation of halobetasol propionate 0.01%/tazarotene 0.045% lotion

Document Type

Conference Proceeding

Publication Date


Publication Title

Journal of Investigative Dermatology


Psoriasis is an immune-mediated disease that may have frequent remissions/exacerbations. Treating psoriasis by combining tazarotene (TAZ) with a topical corticosteroid, such as halobetasol propionate (HP), may enhance efficacy while reducing side effects of HP, which limit long-term use. TAZ also sustains response posttreatment and may play a role in maintenance therapy. This 1-year, open-label study assessed a fixed-combination, once-daily HP 0.01%/TAZ 0.045% lotion in participants with moderate-to-severe psoriasis. HP/TAZ was stopped for those achieving treatment success (Investigator Global Assessment [IGA] score of clear [0] or almost clear [1]) at wk 8; those without treatment success continued with once-daily HP/TAZ. At wk 12, participants demonstrating ≥1-grade IGA improvement from baseline continued and were managed in 4-wk cycles (no treatment success: continued HP/TAZ; treatment success: no treatment until next evaluation). Maximum continuous exposure was 24 wk. Of 550 participants with post-baseline safety data, 318 (57.8%) achieved treatment success; 54.4% of those within the first 8 wk. A post hoc analysis evaluated maintenance of effect in participants that were enrolled ≥8 wk and who achieved clear during the study (n=56). Of these participants: 28.6% did not require any HP/TAZ retreatment after first achievement of clear, 53.6% did not require retreatment for ≥85 days, 62.5% for ≥57 days, and 83.9% for ≥29 days. Though the study design was limited by requiring individuals to stop using HP/TAZ lotion at the time of first treatment success, many patients achieved clear skin, half of whom did not require retreatment for at least 3 months. These data indicate a longer maintenance of therapeutic effect with HP 0.01%/TAZ 0.045% lotion.


Funding: Ortho Dermatologics





First Page


This document is currently not available here.